子宫腺肌病非手术治疗 |
|
|
|
|
子宫腺肌病患者药物治疗进展 |
BabooKalianee Devi( ),陈正云,张信美*( ) |
浙江大学医学院附属妇产科医院妇二科, 浙江 杭州 310006 |
|
Progress on medical treatment in the management of adenomyosis |
Baboo Kalianee Devi( ),CHEN Zhengyun,ZHANG Xinmei*( ) |
Department of Gynecology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China |
1 |
MARJORIBANKS J , AYELEKE R O , FARQUHAR C et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea[J]. Cochrane Database Syst Rev, 2015, (7): CD001751
|
2 |
LETHABY A , AUGOOD C , DUCKITT K et al. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding[J]. Cochrane Database Syst Rev, 2007, (4): CD000400
|
3 |
ITAM S P, AYENSU-COKER L, SANCHEZ J, et al. Adenomyosis in the adolescent population: a case report and review of the literature[J/OL]. J Pediatr Adolesc Gynecol, 2009, 22(5): e146-e147.
|
4 |
SCHAFER A I . Effects of nonsteroidal anti-inflammatory therapy on platelets[J]. Am J Med, 1999, 106 (5B): 25S- 36S
|
5 |
HAWKEY C J . COX-2 inhibitors[J]. Lancet, 1999, 353 (9149): 307- 314
doi: 10.1016/S0140-6736(98)12154-2
|
6 |
VERCELLINI P , VIGANò P , SOMIGLIANA E et al. Endometriosis:pathogenesis and treatment[J]. Nat Rev Endocrinol, 2014, 10 (5): 261- 275
doi: 10.1038/nrendo.2013.255
|
7 |
TSUI K H , LEE W L , CHEN C Y et al. Medical treatment for adenomyosis and/or adenomyoma[J]. Taiwan J Obstet Gynecol, 2014, 53 (4): 459- 465
doi: 10.1016/j.tjog.2014.04.024
|
8 |
SHAABAN O M , ALI M K , SABRA A M et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri:a randomized clinical trial[J]. Contraception, 2015, 92 (4): 301- 307
doi: 10.1016/j.contraception.2015.05.015
|
9 |
FERRERO S , REMORGIDA V , VENTURINI P L . Endometriosis[J]. BMJ Clin Evid, 2010, 2010 pii:0802
|
10 |
STEGEMAN B H , DE BASTOS M , ROSENDAAL F R et al. Different combined oral contraceptives and the risk of venous thrombosis:systematic review and network meta-analysis[J]. BMJ, 2013, 347 f5298
doi: 10.1136/bmj.f5298
|
11 |
RADZINSKY V E , KHAMOSHINA M B , NOSENKO E N et al. Treatment strategies for pelvic pain associated with adenomyosis[J]. Gynecol Endocrinol, 2016, 32 (sup2): 19- 22
doi: 10.1080/09513590.2016.1232673
|
12 |
SHENG J , ZHANG W Y , ZHANG J P et al. The LNG-IUS study on adenomyosis:a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis[J]. Contraception, 2009, 79 (3): 189- 193
doi: 10.1016/j.contraception.2008.11.004
|
13 |
李雷, 冷金花, 史精华 et al. LNG-IUS治疗子宫腺肌病相关经量过多的前瞻性研究[J]. 中华妇产科杂志, 2016, 51 (6): 424- 430 LI Lei , LENG Jinhua , SHI Jinhua et al. A prospective study on the effects of levonorgestrel-releasing intrauterine system for adenomyosis with menorrhagia[J]. Chinese Journal of Obstetrics and Gynecology, 2016, 51 (6): 424- 430
doi: 10.3760/cma.j.issn.0529-567x.2016.06.005
|
14 |
PETTA C A , FERRIANI R A , ABRAO M S et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis[J]. Hum Reprod, 2005, 20 (7): 1993- 1998
doi: 10.1093/humrep/deh869
|
15 |
KRIPLANI A , SINGH B M , LAL S et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia[J]. Int J Gynaecol Obstet, 2007, 97 (3): 190- 194
doi: 10.1016/j.ijgo.2007.01.009
|
16 |
LEE K H , KIM J K , LEE M A et al. Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis[J]. Arch Gynecol Obstet, 2016, 294 (3): 561- 566
doi: 10.1007/s00404-016-4105-y
|
17 |
ZHANG P , SONG K , LI L et al. Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis[J]. Med Princ Pract, 2013, 22 (5): 480- 483
doi: 10.1159/000351431
|
18 |
MAIA H , HADDAD C , CASOY J et al. Effect of a hormone-releasing intrauterine system (Mirena(?)) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection[J]. Int J Womens Health, 2012, 4 175- 183
|
19 |
YU Q , ZHANG S , LI H et al. Dienogest for treatment of endometriosis in women:a 28-week, open-label, extension study[J]. J Womens Health(Larchmt), 2019, 28 (2): 170- 177
doi: 10.1089/jwh.2018.7084
|
20 |
FAWZY M , MESBAH Y . Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis:a prospective clinical trial[J]. Arch Gynecol Obstet, 2015, 292 (6): 1267- 1271
doi: 10.1007/s00404-015-3755-5
|
21 |
OSUGA Y , FUJIMOTO-OKABE H , HAGINO A . Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis:a randomized, double-blind, multicenter, placebo-controlled study[J]. Fertil Steril, 2017, 108 (4): 673- 678
doi: 10.1016/j.fertnstert.2017.07.021
|
22 |
NERⅡSHI K , HIRATA T , FUKUDA S et al. Long-term dienogest administration in patients with symptomatic adenomyosis[J]. J Obstet Gynaecol Res, 2018, 44 (8): 1439- 1444
doi: 10.1111/jog.2018.44.issue-8
|
23 |
MATSUSHIMA T , AKIRA S , FUKAMI T et al. Efficacy of hormonal therapies for decreasing uterine volume in patients with adenomyosis[J]. Gynecol Minim Invasive Ther, 2018, 7 (3): 119- 123
doi: 10.4103/GMIT.GMIT_35_18
|
24 |
PONPUCKDEE J , TANEEPANICHSKUL S . The effects of implanon in the symptomatic treatment of endometriosis[J]. J Med Assoc Thai, 2005, 88 Suppl 2 S7- S10
|
25 |
WU J , HUANG Y , CHEN L et al. Treatment of adenomyosis with subcutaneous etonogestrel implants:a clinical observational study in 17 patients[J]. Med Sci Monit, 2018, 24 6085- 6092
doi: 10.12659/MSM.908979
|
26 |
NELSON J R , CORSON S L . Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist:a case report[J]. Fertil Steril, 1993, 59 (2): 441- 443
doi: 10.1016/S0015-0282(16)55704-5
|
27 |
KHAN K N , KITAJIMA M , HIRAKI K et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy[J]. Hum Reprod, 2010, 25 (3): 642- 653
doi: 10.1093/humrep/dep437
|
28 |
PIERCE S J , GAZVANI M R , FARQUHARSON R G . Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis:a randomized trial with a 6-year follow-up[J]. Fertil Steril, 2000, 74 (5): 964- 968
doi: 10.1016/S0015-0282(00)01537-5
|
29 |
TANG H , WU R , LI X et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage Ⅲ-Ⅳ endometriosis:Randomized controlled study[J]. J Obstet Gynaecol Res, 2017, 43 (10): 1550- 1554
doi: 10.1111/jog.2017.43.issue-10
|
30 |
孙长亮.超小剂量米非司酮治疗子宫腺肌病患者的疗效观察[J/CD].实用妇科内分泌杂志(电子版), 2016, 3(2): 116, 118. SUN Changliang. Efficacy of low-dose mifepristone in treatment of adenomyosis[J/CD]. Journal of Practical Gynecologic Endocrinology(Electronic Edition), 2016, 3(2): 116, 118. (in Chinese)
|
31 |
NEWFIELD R S , SPITZ I M , ISACSON C et al. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia[J]. Clin Endocrinol(Oxf), 2001, 54 (3): 399- 404
doi: 10.1046/j.1365-2265.2001.01026.x
|
32 |
刘芳, 王承秀 . 孕三烯酮与米非司酮治疗子宫腺肌病80例临床效果分析[J]. 现代诊断与治疗, 2014, 25 (13): 2996- 2997 LIU Fang , WANG Chengxiu . Clinical analysis of gestrinone and mifepristone in treatment of 80 patients with adenomyosis[J]. Modern Diagnosis & Treatment, 2014, 25 (13): 2996- 2997
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|